Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines. - Wikidata - wikimedia - TriplyDB

Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines.

Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines.

http://www.wikidata.org/entity/Q34165497

about

Immune effects of trastuzumab Enzymatic discovery of a HER-2/neu epitope that generates cross-reactive T cells.AE37: a novel T-cell-eliciting vaccine for breast cancer.Vaccination for the prevention and treatment of breast cancer with special focus on Her-2/neu peptide vaccines.Repositioning therapeutic cancer vaccines in the dawning era of potent immune interventions.Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines.Peptide-based vaccination and induction of CD8+ T-cell responses against tumor antigens in breast cancer.Results of a Phase Ib Trial of Combination Immunotherapy with a CD8+ T Cell Eliciting Vaccine and Trastuzumab in Breast Cancer Patients.Novel epitope evoking CD138 antigen-specific cytotoxic T lymphocytes targeting multiple myeloma and other plasma cell disorders.Progress in Vaccine Therapies for Breast Cancer.

P2860

Q35057976-8207E21E-8348-4015-842B-36F68A98D4FB Q36487452-9D33CB37-1CCF-4F31-822C-6ED90F1FAD57 Q37927091-A4BE568E-7EB1-48C0-85F5-C5ED0768418B Q38076053-4684EFBF-AFB2-41E8-8563-1F43DC54C979 Q38149916-5B5007B1-460D-4F7A-99F1-FB67ED72DAE4 Q38215394-80D4FD79-24F5-40B4-9FC4-525415044B13 Q38293525-C8323650-2173-46F5-80CC-0D8F8F16D619 Q38896822-7B523B4D-D8F8-4BBE-8271-273900903843 Q39477274-8C88D7D1-E84A-46E9-BFA4-0EFBE8EB3B09 Q48556381-F3D8A15C-0760-4D1B-B89E-DB5C92859AE5

P2860

Comparison of different HER2/neu vaccines in adjuvant breast cancer trials: implications for dosing of peptide vaccines.

http://www.wikidata.org/entity/Q34165497

description

2011 nî lūn-bûn

@nan

2011 թուականի Փետրուարին հրատարակուած գիտական յօդուած

@hyw

2011 թվականի փետրվարին հրատարակված գիտական հոդված

@hy

2011年の論文

@ja

2011年論文

@yue

2011年論文

@zh-hant

2011年論文

@zh-hk

2011年論文

@zh-mo

2011年論文

@zh-tw

2011年论文

@wuu

name

Comparison of different HER2/n ...... or dosing of peptide vaccines.

@ast

Comparison of different HER2/n ...... or dosing of peptide vaccines.

@en

Comparison of different HER2/n ...... or dosing of peptide vaccines.

@nl

type

label

Comparison of different HER2/n ...... or dosing of peptide vaccines.

@ast

Comparison of different HER2/n ...... or dosing of peptide vaccines.

@en

Comparison of different HER2/n ...... or dosing of peptide vaccines.

@nl

prefLabel

Comparison of different HER2/n ...... or dosing of peptide vaccines.

@ast

Comparison of different HER2/n ...... or dosing of peptide vaccines.

@en

Comparison of different HER2/n ...... or dosing of peptide vaccines.

@nl

P1433

Q34165497-864120B2-AFA2-4669-98DE-7FC0B0933702

P1476

Q34165497-D82E2F59-F4DA-4A9C-9722-6E8E15F6FB03

P2093

Q34165497-63325950-8E84-4EC2-A5C7-181926140177

Q34165497-650C8C4B-D87D-469D-AB4A-A5555D004AE0

Q34165497-76DB82EB-7C9E-4465-9AA5-FA96F5C119D4

Q34165497-7D8911DC-76CB-4ECF-81C0-7F055290A329

Q34165497-7E20C686-CA2C-43E8-99EE-0E16FB1F6542

Q34165497-9E6E3417-2E14-436C-81FE-6C9449EBED4C

Q34165497-D06D3A27-FAB3-496B-A0A0-16830692F2B7

Q34165497-E8823366-454A-4C16-81FB-9D27B79D848E

Q34165497-F20558AE-35C0-4BB3-B77A-0518BAF4936D

Q34165497-FAAF246F-3982-43EC-8BAE-C1CF56B38669

P2860

Q34165497-12822959-FCC6-4B63-B28F-6B142A0BEAD0

Q34165497-2DB1F791-1551-4B25-A7EF-0B56A9E87B78

Q34165497-30D45FFD-7DC4-4590-B661-59041F362584

Q34165497-336C7974-3E8D-472B-9C12-949E10F543B5

Q34165497-3F1A9A83-AF3F-4BC5-A7FF-EE296D05F7DD

Q34165497-4024C292-4BA3-47A7-84EE-0C5914FFE398

Q34165497-5CA2AC11-FF24-4929-BD95-18EFF8AF4FF0

Q34165497-6F93DCAB-462F-4FBD-B4EC-23FB328F5AE2

Q34165497-75B90216-67C4-46E1-9E81-5D19A77323A5

Q34165497-81456408-276B-47C5-B86D-A4CE3B5BBDD2

P304

Q34165497-21E3AC76-5AC3-4215-B53E-9EB6BCC67471

P31

Q34165497-C0DEBEB0-3C55-4B98-A073-CDB0EB70F2DE

P356

Q34165497-9A80164A-B75D-48DA-AC45-F7A5F6D4C753

P433

Q34165497-E264FF49-0527-490A-A66A-4BF96F30ADE1

P478

Q34165497-FE17B155-A301-4CD5-B32F-E67672DE29BF

P577

Q34165497-E57BA804-34E4-480A-A3E4-BFD1A21F4B05

P698

Q34165497-5CE4CAE6-6E64-47E1-BA37-26E70CEEA39F

P356

P1433

Expert Review of Vaccines

P1476

Comparison of different HER2/n ...... or dosing of peptide vaccines.

@en

P2093

Alan K Sears

http://www.w3.org/2001/XMLSchema#string

Elizabeth A Mittendorf

http://www.w3.org/2001/XMLSchema#string

George E Peoples

http://www.w3.org/2001/XMLSchema#string

Guy T Clifton

http://www.w3.org/2001/XMLSchema#string

Jarrod P Holmes

http://www.w3.org/2001/XMLSchema#string

Jeremy D Gates

http://www.w3.org/2001/XMLSchema#string

Kevin S Clive

http://www.w3.org/2001/XMLSchema#string

Linda C Benavides

http://www.w3.org/2001/XMLSchema#string

Mark G Carmichael

http://www.w3.org/2001/XMLSchema#string

Sathibalan Ponniah

http://www.w3.org/2001/XMLSchema#string

P2860

Progress and controversies in developing cancer vaccines.

Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer

Peptide and dendritic cell vaccines.

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer.

Optimized DNA vaccines to specifically induce therapeutic CD8 T cell responses against autochthonous breast tumors.

Toll-like receptor ligands energize peptide vaccines through multiple paths.

Combined clinical trial results of a HER2/neu (E75) vaccine for the prevention of recurrence in high-risk breast cancer patients: U.S. Military Cancer Institute Clinical Trials Group Study I-01 and I-02.

Phase I clinical trial of a HER-2/neu peptide (E75) vaccine for the prevention of prostate-specific antigen recurrence in high-risk prostate cancer patients.

Laboratory analysis of T-cell immunity.

Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide.

P304

201-210

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1586/ERV.10.167

http://www.w3.org/2001/XMLSchema#string

P433

2

http://www.w3.org/2001/XMLSchema#string

P478

10

http://www.w3.org/2001/XMLSchema#string

P577

2011-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

21332269

http://www.w3.org/2001/XMLSchema#string